StockData
Immunovant, Inc. logo

Immunovant, Inc. (IMVT) stock

IMVTNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends March 31
Financials through Q1 FY2027, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 9, 2026Score 6/30
$33.21−0.07 (-0.21%)

Close on Nov 17, 2026Market cap $6.86BP/E –Yield –

Immunovant operating cash flow

Operating cash flow is the cash the business generates from its day-to-day operations.

Immunovant's operating cash flow for the twelve months ending Jun 30, 2026 was -$414.30M. For fiscal 2026 it was -$407.31M. The highest annual figure on record is -$28.55M in fiscal 2019.

Annual operating cash flow

PeriodPeriod endValueChange
FY2026Mar 31, 2026-$407.31M–
FY2025Mar 31, 2025-$375.87M–
FY2024Mar 31, 2024-$214.23M–
FY2023Mar 31, 2023-$188.19M–
FY2022Mar 31, 2022-$106.11M–
FY2021Mar 31, 2021-$83.33M–
FY2020Mar 31, 2020-$53.36M–
FY2019Mar 31, 2019-$28.55M–

Quarterly operating cash flow

Change is against the same quarter a year earlier.

Periods
PeriodPeriod endValueChange
Q1 FY2027CQ2 2026Jun 30, 2026-$124.41M–
Q4 FY2026CQ1 2026Mar 31, 2026-$95.06M–
Q3 FY2026CQ4 2025Dec 31, 2025-$92.33M–
Q2 FY2026CQ3 2025Sep 30, 2025-$102.52M–
Q1 FY2026CQ2 2025Jun 30, 2025-$117.41M–
Q4 FY2025CQ1 2025Mar 31, 2025-$110.64M–
Q3 FY2025CQ4 2024Dec 31, 2024-$100.39M–
Q2 FY2025CQ3 2024Sep 30, 2024-$88.65M–
Q1 FY2025CQ2 2024Jun 30, 2024-$76.20M–
Q4 FY2024CQ1 2024Mar 31, 2024-$59.70M–
Q3 FY2024CQ4 2023Dec 31, 2023-$47.10M–
Q2 FY2024CQ3 2023Sep 30, 2023-$60.06M–
Q1 FY2024CQ2 2023Jun 30, 2023-$47.37M–
Q4 FY2023CQ1 2023Mar 31, 2023-$55.79M–
Q3 FY2023CQ4 2022Dec 31, 2022-$46.40M–
Q2 FY2023CQ3 2022Sep 30, 2022-$20.19M–
Q1 FY2023CQ2 2022Jun 30, 2022-$65.82M–
Q4 FY2022CQ1 2022Mar 31, 2022-$32.96M–
Q3 FY2022CQ4 2021Dec 31, 2021-$31.90M–
Q2 FY2022CQ3 2021Sep 30, 2021-$20.05M–
Q1 FY2022CQ2 2021Jun 30, 2021-$21.21M–
Q4 FY2021CQ1 2021Mar 31, 2021-$22.50M–
Q3 FY2021CQ4 2020Dec 31, 2020-$22.82M–
Q2 FY2021CQ3 2020Sep 30, 2020-$24.22M–
Q1 FY2021CQ2 2020Jun 30, 2020-$13.80M–
Q4 FY2020CQ1 2020Mar 31, 2020-$27.47M–
Q1 FY2020CQ2 2019Jun 30, 2019-$8.33M–
Q4 FY2019CQ1 2019Mar 31, 2019-$450–

More Immunovant figures

See a number that looks wrong?